1364267-33-3

Upstream product

• 22717-56-2 4-bromo-2-Hydroxybenzoic Acid Methylester 
• 1666-28-0 4-bromosalicylic acid 
• 1364267-24-2 (R)-methyl 4-bromo-2-(1-(2-(trifluoromethyl)phenyl)ethoxy)benzoate 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1364267-44-6 (R)-methyl 4-(2-amino-5-bromopyridin-3-yl)-2-(1-(2-(trifluoromethyl)phenyl)ethoxy)benzoate 
• 1364267-55-9 C₂₂H₂₀BF₃N₂O₅ 
• 1364267-93-5 (R)-methyl 4-(2-amino-5-(4-((dimethylamino)methyl)thiophen-2-yl)pyridin-3-yl)-2-(1-(2-(trifluoromethyl)phenyl)ethoxy)benzoate 
• 1364268-99-4 (R)-4-(2-amino-5-(4-((dimethylamino)methyl)thiophen-2-yl)pyridin-3-yl)-2-(1-(2-(trifluoromethyl)phenyl)ethoxy)benzamide 

Relevant academic research and scientific papers

Imidazo[1,2-a]pyridine compound, and preparation method and applications thereof

The invention discloses an imidazo[1,2-a]pyridine compound, and a preparation method and applications thereof. The imidazo[1,2-a]pyridine compound can inhibit the activity of NEK2 kinases as an NEK2 micro-molecular inhibitor with a novel structure. The in

Design of potent and selective hybrid inhibitors of the mitotic kinase nek2: Structure-activity relationship, structural biology, and cellular activity

We report herein a series of Nek2 inhibitors based on an aminopyridine scaffold. These compounds have been designed by combining key elements of two previously discovered chemical series. Structure based design led to aminopyridine (R)-21, a potent and selective inhibitor able to modulate Nek2 activity in cells.